Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Numinus Wellness ( (TSE:NUMI) ) has issued an announcement.
Numinus Wellness Inc. reported a 16.4% increase in revenue for Q4 Fiscal 2024, achieving a gross profit of $0.3 million and a cash position of $2.0 million. The company has transitioned to a leaner operation, focusing on its Cedar Clinical Research and practitioner training businesses, which are experiencing robust growth. Significant developments include the sale of its U.S. Clinic Network to Stella, leadership changes with Michael Tan as CEO, and the approval of its Psychedelic-Assisted Therapy Training Program in Colorado. These strategic moves are expected to enhance the company’s position in the mental health industry and provide new growth opportunities.
More about Numinus Wellness
Numinus Wellness Inc. is a mental health care company focused on innovative behavioral health treatments, particularly emphasizing safe, evidence-based psychedelic-assisted therapies. The company is involved in clinical research and practitioner training, aiming to expand the application of psychedelic-assisted therapy.
Technical Sentiment Signal: Sell
Current Market Cap: C$13.86M
For a thorough assessment of NUMI stock, go to TipRanks’ Stock Analysis page.